ArticleCell cycle (Georgetown, Tex.)2015

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myeloma.

Megan Y Murray et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.